Sai Life Sciences Achieves EcoVadis Platinum Rating, Joining the Top 1% of Companies Assessed Worldwide
16.6.2026 14:27:00 CEST | Business Wire | Press release
Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development, and manufacturing organizations (CRDMOs) has secured the EcoVadis Platinum Rating 2026, placing it among the top 1% of companies assessed worldwide for sustainability performance. With an overall score of 87/100 and a 99th percentile ranking, Sai Life Sciences has achieved Platinum Medal in ‘Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations’ category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616260047/en/

Sai Life Sciences achieves EcoVadis Platinum Rating, joining the top 1% of companies assessed worldwide
Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Sustainability is becoming one of the defining measures of excellence in our industry. The ability to innovate, grow and create impact must be matched by an equal commitment to operating responsibly. Securing the EcoVadis Platinum Rating reflects the standards we have set for ourselves and the choices we have made over the years to build a resilient, future-ready organization.”
EcoVadis is among the world's most widely recognized sustainability ratings providers, assessing companies across Environment, Labour & Human Rights, Ethics, and Sustainable Procurement.
The recognition reflects sustained progress across all four EcoVadis assessment pillars. Alongside its environmental initiatives - including a 100% renewable-powered manufacturing site, significant reductions in freshwater dependency, and investments in ecosystem restoration - Sai Life Sciences has strengthened its Labour & Human Rights practices through SA8000 certification and alignment with living wage principles. The company has also enhanced governance through board-level oversight of sustainability and ethics, while reinforcing responsible procurement through supplier assessments and ISO 28000-certified supply chain security practices.
The EcoVadis Platinum Rating builds on Sai Life Sciences' broader sustainability commitments and progress. In 2023, the company joined the Science Based Targets initiative (SBTi), committing to ambitious, science-based greenhouse gas reduction targets across its operations and value chain. In 2020, it became the first India-headquartered company to join Pharmaceutical Supply Chain Initiative (PSCI) membership. Through initiatives such as its partnership with DHL GoGreen to reduce logistics-related emissions and value-chain engagement, Sai Life Sciences continues to advance a sustainability agenda focused on measurable impact, accountability, and long-term value creation.
About Sai Life Sciences
Sai Life Sciences is a full-service Contract Research, Development & Manufacturing Organization (CRDMO) working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules and emerging modalities. With operations across India, the UK, and the US, Sai Life Sciences offers deep scientific expertise, world-class infrastructure, and a culture of excellence focused on quality, safety, and sustainability. For more details visit: www.sailife.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260616260047/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF and ISIPCA Mark 10 Years of Joint Scent Design and Creation Master’s-Level Program16.6.2026 17:00:00 CEST | Press release
A pioneering perfumery program that develops industry-ready talent IFF — a global leader in flavors, fragrances, food ingredients and health & biosciences — celebrates the 10th anniversary of its industry-leading accredited master's-level program for scent design and creation, developed in partnership with ISIPCA, the world-renowned school for careers in perfume, cosmetics and food flavors. Since its launch in 2016, the IFF ISIPCA program has trained more than 180 professionals from 40 countries, with 130 graduates to date, and a 100% job landing rate up to six months after graduation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615461626/en/ The IFF ISIPCA Scent Design and Creation program has been pioneering fragrance education and excellence since 2016. “Over the past decade, IFF ISIPCA has built a strong pipeline of diverse, high-potential fragrance experts, combining creative excellence, scientific expertise and a
Fenchurch Advisory Partners to Combine With Broadhaven Capital Partners, Creating the Preeminent International Investment Bank Serving the Financial Services Sector16.6.2026 16:30:00 CEST | Press release
Fenchurch Advisory Partners has entered into a definitive agreement to combine with Broadhaven Capital Partners, a leading independent advisory firm to the financial technology and financial services sectors in North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616214669/en/ Fenchurch is one of the most respected investment banking advisory firms dedicated exclusively to the financial services sector. With offices in London, New York and Paris, Fenchurch provides trusted, independent advice to corporates and financial sponsors across insurance, asset and wealth management, banking, and specialty finance. In 2025, Fenchurch advised on 27 transactions, ranking as the number one adviser to the financial services sector in the UK and Europe. Founded in 2009, Broadhaven has established itself as a premier investment bank advising corporates and financial sponsors on M&A, capital raising, and strategic transactions,
Svante’s Solid Sorbent Filter Technology Named to Fast Company’s 2026 World Changing IdeasAwards List16.6.2026 16:00:00 CEST | Press release
The recognition highlights Svante’s nanoengineered filters for CO₂ capture and removal This year’s awards, featured on fastcompany.com, highlight 191 outstanding projects across 14 categories. Svante Technologies Inc. (Svante), a purpose-driven integrated carbon management company, today announced that its nanoengineered solid sorbent filter technology has been named to Fast Company’s 2026 World Changing Ideas list, one of the world’s most selective recognitions for innovations tackling climate and sustainability challenges. The honour recognizes Svante’s proprietary filter platform, which enables high-performance capture and removal of CO₂ from industrial emissions and the air, as well as other critical gas separation applications, particularly where chemical processes do not perform well. This year’s awards, featured on fastcompany.com, highlight 191 outstanding projects across 14 categories. A panel of Fast Company editors and reporters evaluated more than 1,500 entries based on the
AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions16.6.2026 16:00:00 CEST | Press release
Investment supports global expansion and continued innovation in AI-powered MRI technologies that help healthcare providers improve imaging efficiency, increase capacity and expand patient access AIRS Medical (“the Company”), a global leader in AI solutions for medical imaging, today announced a strategic growth investment from TA Associates (“TA”), a leading global private equity firm. The investment will help fuel AIRS Medical’s next phase of global expansion, advancement of its AI-powered radiology technology solutions and ongoing product innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616325248/en/ Founded in 2018, AIRS Medical develops AI-native magnetic resonance imaging (“MRI”) acceleration and reconstruction software designed to support MRI speed, image quality and workflow performance. Healthcare organizations and leading academic institutions are adopting AIRS Medical's technologies to expand imaging
Clearlake Capital Closes on $14.8 Billion to Capitalize on AI-Driven Transformation and Continue Sector-Focused Investment Strategy16.6.2026 15:00:00 CEST | Press release
Fund VIII Reflects Strong Global Investor Support for Clearlake’s Integrated Platform, Operational Value-Creation Model, and AI-Enabled Investment Approach Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced the successful close of its eighth flagship fund, Clearlake Capital Partners VIII (“Fund VIII”), alongside related co-investment vehicles and separately managed accounts. Together, these vehicles represent $14.8 billion of capital commitments and position Clearlake to continue investing behind the secular trends reshaping industries, including artificial intelligence, software modernization, digital transformation, and operational efficiency. The successful fundraise comes amid a highly competitive and selective fundraising environment for private markets and underscores continued investor confidence in Clearlake's different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom